Skip to content

Psilocybin research published in 2026

Page 14 of 25: studies 261 to 280 of 481, newest first. Back to the psilocybin overview

Studies

Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA

AJPM Focus May 1, 2026 R Andrew Yockey, Amber Amis, Elise Devier et al.

AbstractIntroduction Psilocybin, a naturally occurring psychedelic compound found in certain mushroom species, has gained substantial clinical, scientific, and cultural attention in recent years. Despite this growing interest and evolving policy landscape, nationally representative estimates of recent psilocybin use in the United States remain limited. Understanding the current prevalence and...

Trip killers: Addressing a critical knowledge gap in psychedelic research.

Journal of Psychopharmacology May 1, 2026 Brian O'Mahony, Colm Harrington, Andrew Harkin et al.

Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a "bad trip." Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require...

Effects of psychedelic use on authoritarian attitudes revisited.

Journal of Psychopharmacology May 1, 2026 Otto Simonsson, Taylor Lyons, Joseph Marks et al.

Previous research suggests that psychedelics may, under certain conditions, decrease authoritarian attitudes, but larger and more rigorously designed studies are needed to confirm these findings. We aimed to examine the effects of psychedelic use on authoritarian attitudes. Using data from three separate studies with different designs and populations, we investigated the relationship between...

Associations between psychedelic use and migraine history in Swedish twins.

Journal of Psychopharmacology May 1, 2026 Otto Simonsson, Sunjuri Sun, Laura W. Wesseldijk et al.

While psychedelics have shown initial promise in the treatment of migraine, experimental studies have relied on small and homogenous samples, which limit the reliability and generalizability of findings. These limitations underscore the complementary value of other research designs that leverage larger and more representative samples. This cross-sectional study included three cohorts of twins...

Correction: Catatonia Associated With First-Time Psilocybin Exposure: A Case Report.

Cureus May 1, 2026 Jasbir Singh, Pranathi Mruthyunjaya correction

In this case report, we highlight a 28-year-old male patient with predominantly retarded type of catatonia following a single incidence of psilocybin ingestion. This patient presented with a history of six months of mutism and inability to feed himself after consuming psilocybin for the first time. He did not have any history of psychiatric illness or substance use. Imaging and laboratory...

Therapeutic Potential of Psilocybin in Alcohol and Opioid Use Disorders: A Promising Role for Psychedelics

Pharmaceutical Sciences April 30, 2026 Elmira Zolali, Lance R Mcmahon, Samuel Obeng

Please don't use dangerous characters * Last Name Please don't use dangerous characters * Email Address Please enter a email address * Comments Please don't use dangerous characters * Security code The entered code is invalid. Generate New Image Type the code from the image Abstract View: 388 Your browser does not support the canvas element. yearsJanFebMarAprMayJunJulAugSepOctNovDec...

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings

Repository for Publications and Research Data April 30, 2026 Kurt Stocker, Matthias Hartmann, Frederick S. Barrett et al.

Objectives: For English, the validated part of Psychedelic Experience Scale (PES48) is a four-factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and two more non-mystical factors (visual experience...

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption.

Behavioral Sciences April 30, 2026 Dylan Briggs, Thomas B Sease, Ruthie Menou et al.

Mystical experiences are characterized by a profound sense of interconnectedness and transcendence of ordinary reality. These experiences can facilitate feelings of connectedness with oneself and others and have been documented as leading to significant positive changes in thoughts, emotions, and behavior. The purpose of the present study was to evaluate the extent to which the four mindfulness...

DOI: 10.3390/bs16050686 (opens in new tab) Full text (opens in new tab) Mystical experiences Near death experiences Psychedelic use Psychological flexibility +1

Evaluating the evidence for repressed memory recovery in psychedelic contexts

Psychopharmacology April 29, 2026 Anne-Fiona Griesfeller, Lotte Kooman, Lilian Kloft-Heller et al.

RATIONALE: Reports of resurfaced repressed memories during psychedelic experiences have circulated for decades and still emerge today. However, the veracity of repressed memories remains debated, and the mechanisms through which psychedelics might recover alleged repressed memories are unclear. OBJECTIVES: This scoping review aimed to provide an overview of the literature on repressed memory in...

Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations

medRxiv Preprint Server April 28, 2026 Sandeep M. Nayak, Nathan D. Sepeda, Matthew Nielsen Dick et al. preprint

Background Psilocybin has increasingly been studied as a therapeutic for psychiatric and neurologic conditions, yet comprehensive cardiovascular safety data are limited. Current trials often exclude individuals with blood pressure ≥140/90 mmHg, criteria established conservatively without robust empirical support.

The Harmonious Dance: A Narrative Review on Psychedelics and Music in Therapeutic Settings.

Current Neuropharmacology April 28, 2026 Hongshuang Wang, Xiaobing Li, Feng Yu et al.

The integration of psychedelics and music in therapeutic settings is gaining recognition for its potential to enhance mental health outcomes. This review synthesizes current evidence on the neurobiological mechanisms underlying this synergy, focusing on receptor-level pathways (e.g., 5-HT2A receptor agonism, BDNF-TrkB signaling) and neural circuit dynamics (e.g., default mode network...

The Alchemy of Mind: Integrating Sanyam and Joriki into the Framework of Fundamental Peace

Preprints.org April 27, 2026 Luis Miguel Gallardo preprint

Ancient contemplative traditions offer sophisticated technologies for cultivating stable states of consciousness underlying sustainable well-being. This integrative review synthesizes empirical and theoretical literature on Patañjali’s Sanyam—the integrated practice of Dharana (concentration), Dhyana (meditative absorption), and Samadhi (non-dual awareness)—and its Zen parallel, Joriki...

Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study.

Journal of Medical Internet Research April 27, 2026 Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al. 2 citations

Mainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow. In this cross-sectional survey study, we outline an estimation framework based on data fusion and combine two surveys:...

Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders.

Trends in Psychiatry and Psychotherapy April 25, 2026 Alberto Barbieri

Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical burden and limited treatment outcomes. Schema Therapy (ST), an integrative psychotherapy rooted in cognitive-behavioral principles, conceptualizes PDs in terms of Early Maladaptive Schemas (EMS)-pervasive cognitive-affective structures formed through...

"Large-Scale and Local Functional Connectivity Changes Following Psilocybin Administration in Methamphetamine Use Disorder.

AJNR. American journal of neuroradiology April 24, 2026 Joga Chaganti, Krista J. Siefried, Veda S Vyakaranam et al.

Methamphetamine (MA) use disorder is associated with widespread disruption of large-scale brain networks involved in cognitive control, attention, and salience processing. Resting-state functional MRI (rs-fMRI) provides a means to characterize these alterations; however, little is known about the capacity for functional network reorganization following targeted intervention. The purpose of this...

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia.

Communications Biology April 24, 2026 Tatum Askey, Daniel Allen-Ross, Daniil Luzyanin et al.

Chronic pain states remain challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin produces a sustained anti-nociceptive effect in chronic neuropathic pain models in male and female mice, mediated primarily by 5-HT2A receptors. Critically, psilocybin significantly potentiates the analgesic efficacy of gabapentin, a standard-of-care treatment,...

Psilocybin use among Basotho healers and non-healers in southern Africa

April 23, 2026 Eli Stark-Elster, Mamosebetsi Sethathi, Breyten Van der Merwe et al.

Reliable documentation of the traditional use of serotonergic psychedelics has long been confined to the Americas. Prevailing narratives often overstate the global prevalence and uniformity of traditional psychedelic use, extrapolating from a limited set of well-documented cases. Here, we report evidence of psilocybin mushroom use among Basotho traditional healers and non-healers in Lesotho and...

Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations.

Research Square April 23, 2026 Leah M Salinsky, Joshua L Fox, Kyra C Diaz et al. preprint

Polysubstance use involving psychostimulants and opioids is increasingly prevalent and associated with elevated overdose risk, relapse vulnerability, and poor treatment outcomes. However, the neurobehavioral consequences of opioid-stimulant use remain poorly understood. We evaluated whether repeated methamphetamine-fentanyl polysubstance treatment disrupts social preference during withdrawal,...

Structural plasticity and enhanced fear extinction following psilocybin in chronically stressed mice.

bioRxiv : the preprint server for biology April 22, 2026 Cory A. Knox, Samuel C Woodburn, Amelia D. Gilbert et al. preprint

The classic psychedelic psilocybin elicits long-lasting neural plasticity and behavioral effects, but prior studies largely examined stress-naive animals. Using longitudinal imaging, we show that psilocybin increases dendritic spine density in frontal cortical neurons and facilitates fear extinction after chronic restraint stress, demonstrating psilocybin's effects in a translationally relevant...

Psilocybin as an alternative to conventional treatments: A systematic review

Gaceta Médica de Caracas April 22, 2026 Deivid Antonio Cahuasqui-Mendoza

Introduction. Limitations of conventional treatments for depression and anxiety, particularly in treatment-resistant cases, have driven interest in alternative therapeutic approaches. Psilocybin, a serotonergic agonist with demonstrated effects on neuroplasticity and large-scale brain networks, has emerged as a promising therapeutic option. Materials and methods: A systematic review of...